Yi Hu

15.8k citations
311 papers · 12.1k · 9 hit papers · h-index 41

Impact in

  • Oncology top 0.2%
    • Cancer Immunotherapy and Biomarkers
    • Lung Cancer Research Studies
    • Inflammatory Biomarkers in Disease Prognosis
    • Lung Cancer Treatments and Mutations
    • Lung Cancer Diagnosis and Treatment
    • Brain Metastases and Treatment

Papers in

    • Cancer Immunotherapy and Biomarkers 60
    • Lung Cancer Research Studies 31
    • Inflammatory Biomarkers in Disease Prognosis 13
    • Lung Cancer Treatments and Mutations 54
    • Lung Cancer Diagnosis and Treatment 16

Yi Hu

293 papers receiving 11.9k citations

Yi Hu's Hit Papers

Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials 2023 · 122 citations
1220+2+4Years since publication5001k1.5k2k2.5k

Peers

Yi Hu
Comparison fields: 5 of 115
  • Oncology 6.5k
  • Pulmonary and Respiratory Medicine 2.6k
  • Cancer Research 855
  • Immunology 556
  • Hepatology 180
Replace Hans Prenen with:
Hans Prenen Belgium
Jing Liang Yang China
Julian R. Molina United States
Matteo Santoni Italy
Ignacio Garrido‐Laguna United States
Yoshiharu Sakai Japan
Ferdinando De Vita Italy
Sang Cheul Oh South Korea
Kensei Yamaguchi Japan
Teppei Morikawa Japan
Yi Hu relative to Hans Prenen Belgium Hans Prenen's profile →
Citations per field
00.5×1.5×1.8×
Hans Prenen · 1×
Citations per year

Countries citing papers authored by Yi Hu

Since Specialization
Citations

This map shows the geographic impact of Yi Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yi Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yi Hu more than expected).

Fields of papers citing papers by Yi Hu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yi Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yi Hu. The network helps show where Yi Hu may publish in the future.

Co-authors

The 25 scholars most cited alongside Yi Hu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Yi Hu Line = papers co-authored together Yi Hu links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 311 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Hit paper breakdown →
20192712
2
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Hit paper breakdown →
20191737
3
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Hit paper breakdown →
2020522
4
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
Hit paper breakdown →
2020490
5
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
Hit paper breakdown →
2020368
6
Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer
Hit paper breakdown →
2021349
7
Programmed Cell Death Tunes Tumor Immunity
Hit paper breakdown →
2022255
8
γδ T cells: origin and fate, subsets, diseases and immunotherapy
Hit paper breakdown →
2023239
9 2018186
10 2019122
11
Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials
Hit paper breakdown →
2023122
12 2015117
13 2019114
14 2020111
15 2015105
16 2018101
17 2021101
18 201997
19 201991
20 202072

About Yi Hu

Yi Hu is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Immunology and Molecular Biology, having authored 311 papers that have together received 12.1k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (60 papers), Lung Cancer Treatments and Mutations (54 papers), Lung Cancer Research Studies (31 papers), Lung Cancer Diagnosis and Treatment (16 papers), Esophageal Cancer Research and Treatment (14 papers), Inflammatory Biomarkers in Disease Prognosis (13 papers), MicroRNA in disease regulation (9 papers) and Hepatocellular Carcinoma Treatment and Prognosis (8 papers). The work is most often cited by research in Oncology (6.5k citations), Pulmonary and Respiratory Medicine (2.6k citations), Cancer Research (855 citations), Immunology (556 citations) and Hepatology (180 citations). Yi Hu has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Yangzhe Wu, Haitao Tao, Jinliang Wang, Shunchang Jiao, Sujie Zhang, Yijia Li, Yixue Xue, Zhibo Zhang, Dan Chen and Jing Liu. Their work appears in journals such as Frontiers in Oncology, Translational Lung Cancer Research, Journal of Thoracic Oncology, Cancer Medicine and Frontiers in Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact